 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Hain Lifescience GmbH |
| Street 1: | Hardwiesenstr. 1 |
| Street 2: | |
| City: | Nehren |
| Province: | Tübingen |
| Post Code: | D-72147 |
| Country: | Germany |
| Phone: | +49 7473 9451 0 |
| Organization Email: | info.mdx.de@bruker.com |
| Web Site: | http://www.hain-lifescience.de |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| Development, manufacture and marketing for rapid and reliable Mycobacteria-Diagnostics based on DNA strip technology (LPA) and direct fluorescence based detection. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| How did you hear about the Stop TB Partnership: | Other partners |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Close contact to NRL/SNRL | |
Geographical Reach | |
| Which country is your headquarters located in: | Germany |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Albania Andorra Argentina Armenia Australia Austria Azerbaijan Bahrain Bangladesh Belarus Belgium Benin Bolivia Bosnia and Herzegovina Botswana Brazil Bulgaria Cambodia Cameroon Canada Chile China Colombia Cote d'Ivoire Croatia Cuba Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Dominican Republic Egypt Eritrea Estonia Eswatini Ethiopia Finland France Gabon Gambia Georgia Germany Ghana Greece Guatemala Guyana Haiti Hungary India Indonesia Israel Italy Japan Kazakhstan Kenya Kuwait Kyrgyzstan Latvia Lesotho Lithuania Luxembourg Malawi Malaysia Mali Mexico Mozambique Namibia Nepal Netherlands Nigeria Norway Pakistan Panama Peru Philippines Poland Portugal Republic of Moldova Republic of Montenegro Republic of Serbia Romania Russian Federation Rwanda Saudi Arabia Senegal Singapore Slovakia Slovenia South Africa Spain Sudan Sweden Switzerland Tajikistan Thailand Togo Trinidad and Tobago Tunisia Turkey Turkmenistan Uganda Ukraine United Arab Emirates United Kingdom of Great Britain and Northern Ireland United Republic of Tanzania United States of America Uruguay Uzbekistan Viet Nam Zambia Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New Diagnostics: In the field of Mycobacteria Diagnostics we offer a wide range of different molecular genetic test systems for the detection of tuberculosis, nontuberculous mycobacteria and leprosy. Our worldwide used test systems enable an efficient TB screening and reliable testing for MDR- and XDR-TB directly from patient specimens using fluorescence-based detection and the well proven LPA-technology. The assays for nontuberculous mycobacteria allow the direct detection of clinically relevant NTMs from pulmonary samples. Furthermore resistance testing for macrolides and aminoglycosides is possible in a second step. The line probe assays "GenoType MTBDRplus" and "GenoType MTBDRsl" are recommended by WHO The new PCR-based FluoroType MTBDR test identifies tuberculosis (TB) pathogens as well as important antibiotic resistance characteristics within three hours from patients specimens. The high degree of automation simplifies and speeds up testing and allows a throughput of up to 96 samples. FluoroType technology also supports the detection of rare or as yet unknown mutations in the target genes. The analysis is carried out automatically by the Fluoro-Software and is clearly presented in the results report. The scope of software can be extended by newly discovered mutants. |
|
Declaration | |
| Declaration of interests: Hain Lifescience is a private for profit organization developing and producing molecular biological assays for detection of Mycobacteria and related drug resistances; parallel to a broad range of other diagnostic applications. | |
| Application date: | January 15, 2009 |
| Last updated: | January 17, 2019 |